June 14, 2018Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com

0:48 Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis https://www.prnewswire.com/news-releases/samus-therapeutics-announces-pu-h71-granted-orphan-drug-designation-and-first-patient-dosed-in-phase-1b-study-in-myelofibrosis-300665566.html 

3:34 U.S. FDA Approves Moxidectin For The Treatment Of River Blindness https://www.prnewswire.com/news-releases/us-fda-approves-moxidectin-for-the-treatment-of-river-blindness-300666114.html

6:38 REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I https://www.prnewswire.com/news-releases/regenxbio-receives-fda-fast-track-designation-for-rgx-111-gene-therapy-for-the-treatment-of-mucopolysaccharidosis-type-i-300665253.html

9:17 U.S. Food and Drug Administration Clears Wearable Device to Treat Opioid Addiction https://www.prnewswire.com/news-releases/us-food-and-drug-administration-clears-wearable-device-to-treat-opioid-addiction-300664443.html

11:07 Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s efforts to foster discovery and development of new tools to fight antimicrobial-resistant infections https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm610503.htm http://www.cidrap.umn.edu/news-perspective/2018/06/fda-head-looks-boost-antibiotic-development

Please check out my weekly podcast AI in Medicine. In this episode, I talk to Dr. Suvas Vajracharya, CEO and Founder, Lightning Bolt Solutions, Inc. Using an AI-based platform, Lightning Bolt manages over 3 million shift hours each month, scheduling 20,000 clinicians at 350 healthcare organizations. Podcast website is aimedicinenews.com.

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/